← back to search

Steven H. Ferris

New York University · US
Area of research
Psychiatry and Mental health · Physiology
Research interest
Research interests include Dementia and Cognitive Impairment Research, Alzheimer's disease research and treatments, Health Systems, Economic Evaluations, Quality of Life, and Cholinesterase and Neurodegenerative Diseases.
h-index
89
citations
49,568
works
399
NIH funding
primary concept
email

Recent publications

Manifestations of Alzheimer’s disease genetic risk in the blood are evident in a multiomic analysis in healthy adults aged 18 to 90
Scientific Reports 2022cited by 27position: middledoi
Exceptionally low likelihood of Alzheimer’s dementia in APOE2 homozygotes from a 5,000-person neuropathological study
Nature Communications 2020cited by 482position: middledoi
Novel Alzheimer Disease Risk Loci and Pathways in African American Individuals Using the African Genome Resources Panel
JAMA Neurology 2020cited by 272position: middledoi
Genetic meta-analysis of diagnosed Alzheimer’s disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing
Nature Genetics 2019cited by 2,772position: contributordoi
A statistical framework for cross-tissue transcriptome-wide association analysis.
2019cited by 347position: contributordoi
Author Correction: Genetic meta-analysis of diagnosed Alzheimer’s disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing
Nature Genetics 2019cited by 58position: contributordoi
A randomized clinical trial to evaluate home-based assessment of people over 75 years old.
2019cited by 6position: contributordoi
Version 3 of the Alzheimer Disease Centers’ Neuropsychological Test Battery in the Uniform Data Set (UDS)
Alzheimer Disease & Associated Disorders 2017cited by 660position: middledoi
Transethnic genome‐wide scan identifies novel Alzheimer's disease loci
Alzheimer s & Dementia 2017cited by 210position: middledoi
Assessment of the genetic variance of late-onset Alzheimer's disease
Neurobiology of Aging 2016cited by 255position: middledoi
<i>ABCA7</i> frameshift deletion associated with Alzheimer disease in African Americans
Neurology Genetics 2016cited by 107position: middledoi
A randomized, double-blind, placebo-controlled trial of resveratrol for Alzheimer disease
Neurology 2015cited by 688position: middledoi
Targeting Prodromal Alzheimer Disease With Avagacestat
JAMA Neurology 2015cited by 232position: middledoi
Tracking Early Decline in Cognitive Function in Older Individuals at Risk for Alzheimer Disease Dementia
JAMA Neurology 2015cited by 203position: middledoi
Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease
New England Journal of Medicine 2014cited by 1,958position: middledoi
Effects of Multiple Genetic Loci on Age at Onset in Late-Onset Alzheimer Disease
JAMA Neurology 2014cited by 196position: middledoi
The Alzheimer's Disease Cooperative Study Prevention Instrument Project: Longitudinal Outcome of Behavioral Measures as Predictors of Cognitive Decline
Dementia and Geriatric Cognitive Disorders Extra 2014cited by 75position: middledoi
Rarity of the Alzheimer Disease–Protective<i>APP</i>A673T Variant in the United States
JAMA Neurology 2014cited by 49position: middledoi
Promising developments in neuropsychological approaches for the detection of preclinical Alzheimer’s disease: a selective review
Alzheimer s Research & Therapy 2013cited by 203position: lastdoi
Language impairment in Alzheimer&amp;#39;s disease and benefits of acetylcholinesterase inhibitors
Clinical Interventions in Aging 2013cited by 168position: firstdoi
Novel White Matter Tract Integrity Metrics Sensitive to Alzheimer Disease Progression
American Journal of Neuroradiology 2013cited by 154position: middledoi
White matter tract integrity metrics reflect the vulnerability of late-myelinating tracts in Alzheimer's disease
NeuroImage Clinical 2013cited by 131position: middledoi
Non-Gaussian diffusion MRI assessment of brain microstructure in mild cognitive impairment and Alzheimer’s disease
Magnetic Resonance Imaging 2013cited by 119position: middledoi
Age and apolipoprotein E genotype influence rate of cognitive decline in nondemented elderly.
Neuropsychology 2013cited by 31position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

David P. Salmon · University of California San Diego4 papers (2013–2017)Reisa A. Sperling · Harvard University4 papers (2013–2015)Maria F. Falangola · Medical University of South Carolina3 papers (2013–2013)Joseph A. Helpern · New York University3 papers (2013–2013)Jens H. Jensen · Medical University of South Carolina3 papers (2013–2013)Paul Aisen · University of Southern California2 papers (2014–2015)James S. Babb · New York University2 papers (2013–2013)Els Fieremans · New York University2 papers (2013–2013)Andreana Benitez · Medical University of South Carolina2 papers (2013–2013)Dorene M. Rentz · Brigham and Women's Hospital2 papers (2013–2015)Rachael Deardorff · Indiana University School of Medicine2 papers (2013–2013)Rebecca E. Amariglio · Harvard University2 papers (2013–2015)Ali Tabesh · New York University2 papers (2013–2013)Stephen Salloway · Brown University1 papers (2014–2014)Sandra Weıntraub · Northwestern University1 papers (2017–2017)Xiao‐Hua Zhou · Harvard University1 papers (2017–2017)Lawrence S. Honig · Columbia University Irving Medical Center1 papers (2014–2014)Alireza Atri · Barrow Neurological Institute1 papers (2017–2017)Feng He · Shanghai University of Traditional Chinese Medicine1 papers (2014–2014)H. Robert Brashear · University of Virginia1 papers (2014–2014)